WHO Expert Committee on Specifications for Pharmaceutical Preparations - WHO Technical Report Series, No. 885 - Thirty-fifth Report
(1999; 168 pages) [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoWHO Expert Committee on Specifications for Pharmaceutical Preparations
Ver el documento1. Introduction
Abrir esta carpeta y ver su contenido2. The international pharmacopoeia and related issues
Abrir esta carpeta y ver su contenido3. International Chemical Reference Substances and Infrared Reference Spectra
Abrir esta carpeta y ver su contenido4. Quality control - national laboratories
Abrir esta carpeta y ver su contenido5. Good manufacturing practices
Abrir esta carpeta y ver su contenido6. Quality systems and inspection
Abrir esta carpeta y ver su contenido7. Other quality assurance topics
Abrir esta carpeta y ver su contenido8. Nomenclature and terminology
Abrir esta carpeta y ver su contenido9. Legal aspects of pharmaceuticals
Abrir esta carpeta y ver su contenido10. Regulatory issues
Abrir esta carpeta y ver su contenido11. Training activities
Ver el documento12. Pharmaceuticals contaminated with diethylene glycol
Ver el documentoAcknowledgements
Ver el documentoReferences
Ver el documentoAnnex 1. List of available International Chemical Reference Substances1
Ver el documentoAnnex 2. List of available International Infrared Reference Spectra1
Abrir esta carpeta y ver su contenidoAnnex 3. General guidelines for the establishment, maintenance and distribution of chemical reference substances
Abrir esta carpeta y ver su contenidoAnnex 4. Good manufacturing practices: authorized person - role, functions and training
Cerrar esta carpetaAnnex 5. Good manufacturing practices: supplementary guidelines for the manufacture of pharmaceutical excipients
Ver el documento1. General considerations
Ver el documento2. Glossary
Ver el documento3. Self-inspection and quality audits
Abrir esta carpeta y ver su contenido4. Equipment
Abrir esta carpeta y ver su contenido5. Materials
Abrir esta carpeta y ver su contenido6. Documentation
Cerrar esta carpeta7. Good practices in production and quality control
Ver el documento7.1 Change control and process validation
Cerrar esta carpeta7.2 Good practices in production
Ver el documento7.2.1 Prevention of cross-contamination
Ver el documento7.2.2 In-process blending/mixing
Ver el documento7.2.3 Control of microbial contamination
Ver el documento7.2.4 Water systems/water quality
Ver el documento7.2.5 Packaging operations
Ver el documento7.2.6 Delivery
Abrir esta carpeta y ver su contenido7.3 Good practices in quality control
Abrir esta carpeta y ver su contenidoAnnex 6. Guidelines for inspection of drug distribution channels
Ver el documentoAnnex 7. Good pharmacy practice in community and hospital pharmacy settings
Abrir esta carpeta y ver su contenidoAnnex 8. National drug regulatory legislation: guiding principles for small drug regulatory authorities
Abrir esta carpeta y ver su contenidoAnnex 9. Provisional guidelines for developing training programmes: inspection and examination of counterfeit pharmaceuticals
Ver el documentoWorld Health Organization Technical Report Series
Ver el documentoSelected WHO Publications of Related Interest
Ver el documentoBack Cover
 
7.2.1 Prevention of cross-contamination

Potential for cross-contamination should be considered in the design of the manufacturing process and facility. The degree to which cross-contamination should be minimized depends on the safety and intended use of the excipient.

The precautions taken to minimize cross-contamination should be appropriate to the conditions of the manufacturing facility and will take account of the range of materials manufactured. When the excipient product is initially recovered, it should be in a clean environment and not exposed to airborne contaminants, such as dust from other excipient or industrial chemicals. Typically, the damp product will be unloaded into clean, covered containers and transported for drying and other manipulations. These subsequent operations should be performed in separate areas or under controlled conditions because once dry, the excipient is more likely to contaminate its environment, including any surrounding products. The primary consideration is that the building and facilities should not contribute to an actual or potential contamination of the excipient.

The air handling systems at the site of manufacture should be designed to prevent cross-contamination. In dedicated areas processing the same excipient, it is permissible to recycle a portion of the exhaust air back into the same area. The adequacy of such a system of operation for multi-use areas, especially if several products are processed simultaneously, should be carefully analysed. In multi-use areas where several products are completely confined in closed vessels and piping systems, filtration of the supply air (combined fresh make-up air and recycled air) is acceptable if the conditions are consistent with other existing regulations (e.g. environmental, safety).

In those areas where the excipient is in a damp or moistened form, such as filter or centrifuge cake, and may be exposed to room air, filter efficiencies in the supply air system as low as 85% may be adequate. In those areas where one or more of the products is being processed in a dry form, such filtration may not be enough to prevent cross-contamination. In all cases, manufacturers should be able to demonstrate the adequacy of their air handling systems.

Excipient manufacturers should have a documented programme identifying all insecticides, pesticides, rodenticides and herbicides used at the site of manufacture. Adequate measures should be taken to prevent these agents contaminating the excipients.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013